Eastern Equine Encephalitis (EEE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Eastern equine encephalitis (EEE) is a
rare yet grave infection resulting in encephalitis or brain inflammation. It is
caused by the EEE virus (EEEV), transmitted through the bite of a mosquito
carrying the virus. Considered one of the most severe forms of arboviral
encephalitis in America, EEE affects individuals differently based on their
age. Those over 50 and under 15 face the highest risk of severe illness. The
onset of severe EEE cases is sudden, marked by intense headache, high fever,
chills, and vomiting. These symptoms can progress to disorientation, seizures,
encephalitis, and coma. Alarming statistics show that approximately one-third
of EEE patients do not survive the infection. Those who do survive often
experience varying degrees of brain damage. The EEE virus, classified within
the Togaviridae family and alphavirus genus, is maintained through a cycle
involving birds and primarily Culiseta melanura mosquitoes found in freshwater
hardwood swamps. To date, no antiviral medication has demonstrated
effectiveness against Eastern equine encephalitis. Supportive care remains the
primary approach, with severe cases often necessitating admission to intensive
care units and ventilatory assistance. Healthcare professionals in areas with
elevated risk of EEE transmission should consider this infection when presented
with aseptic meningitis or encephalitis cases. Any suspected instances should
be promptly reported to local health authorities. The differential diagnosis
encompasses other viral encephalitides like measles, mumps, echovirus, and the
less probable Creutzfeldt–Jakob disease. The fatality rate for EEE is estimated
to be as high as 41% and around 50% of affected patients will experience some
form of neurological impairment. Factors that predict poor outcomes include
severe hyponatremia, abnormal electroencephalograms, and high initial
cerebrospinal fluid pleocytosis. Although these findings might indicate
inflammatory markers, it's intriguing that patients treated with
corticosteroids tend to fare worse than those who aren't treated with them.
Thelansis’s “Eastern Equine
Encephalitis (EEE) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2022 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Eastern
Equine Encephalitis (EEE) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Eastern Equine Encephalitis (EEE) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Eastern Equine Encephalitis (EEE) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment